Regarding the study about COVID-19 patients with CLL who were hospitalized, this is a result actually of an international effort, where we joined the cohorts and the data collected from the US and UK colleagues and the Spanish group and the European Research Initiative on the CLL project. And basically we confirm what we have already shown, so that the mortality rate in patients hospitalized for COVID-19 seems to be higher in patients with CLL, unfortunately...
Regarding the study about COVID-19 patients with CLL who were hospitalized, this is a result actually of an international effort, where we joined the cohorts and the data collected from the US and UK colleagues and the Spanish group and the European Research Initiative on the CLL project. And basically we confirm what we have already shown, so that the mortality rate in patients hospitalized for COVID-19 seems to be higher in patients with CLL, unfortunately. And factors predicting this higher mortality rate are mostly associated with increased age and some relevant key comorbidities. But the disease itself, if well-control, is not, let’s say, adding further risk for the patients hospitalized because of COVID-19.
So we are still trying to better characterize the features related to infection outcome in patient with CLL, and apparently there is no additional risk related to treatment, especially with targeted agents. They do not seem to increase the risk, basically for sure not of developing the infection, but they are not also influencing worse outcome of the infection. But still, the cohort collected so far are not so large, so we definitely need additional data and a longer follow-up to better understand the COVID-19 course in patients with CLL.